BusinessWeek -- Molecular diagnostics company Myriad Genetics Inc. said Monday a study of its Prolaris molecular diagnostic product shows it can accurately predict the survival of patients with prostate cancer.
BusinessWeek -- Molecular diagnostics company Myriad Genetics Inc. said Monday a study of its Prolaris molecular diagnostic product shows it can accurately predict the survival of patients with prostate cancer.